During the morning session, developments were reported at several companies, including the start of a sales collaboration between フライトソリューションズ and 加賀電子 for identity verification devices, 積水化成品工業's full-year upward revision, and 東映アニメーション's operating profit revision. News was also reported on サンテック, including data center projects, and on the start of a clinical trial by ネクセラファーマ and ADRバイオ.
フライトソリューションズ announced that it would begin a sales collaboration with 加賀電子 to promote the adoption of its identity verification solution, introducing new functionality that also supports NFC card readers other than multipayment terminals. In anticipation of a review of face-to-face identity verification methods, the company said it would provide devices tailored to specific applications and support their implementation.
積水化成品工業 announced that it had raised its full-year consolidated operating profit forecast for the fiscal year ending March 2027 from the previous ¥3.10 billion to ¥5.30 billion, and would also raise its annual dividend to ¥25. Portfolio reforms, including the transfer of its European business, increased sales across its businesses, price revisions and fixed-cost reductions contributed to the improvement.
東映アニメーション raised its full-year consolidated operating profit forecast for the fiscal year ending March 2027 to ¥26.4 billion, while lowering its revenue forecast to ¥98.2 billion. The company expects to offset factors behind the first-half shortfall with the postponement of some deliveries of productions into the second half.
サンテック raised its consolidated operating profit forecast for the first half of the fiscal year ending March 2027 to ¥2.38 billion. The company's data center electrical equipment construction business in Malaysia is expected to exceed its plan, with higher gross profit and lower selling, general and administrative expenses expected to contribute.
ネクセラファーマ obtained from Idorsia exclusive development and commercialization rights for lucerastat, a Fabry disease drug candidate, in certain Asia-Pacific regions including Japan, South Korea and Taiwan. The upfront payment under the agreement is approximately ¥1.33 billion, and the company is targeting 2029 for the filing of an approval application.
ADRバイオ announced that a subsidiary had begun a clinical trial of a treatment for chronic limb-threatening ischemia. The company has already entered into a joint research agreement with Nagoya University and aims to commercialize the treatment with a view to obtaining reimbursement coverage.